Please contact our sales representative to learn more information about this reagents.
Background
Iratumumab is a human monoclonal antibody used in the treatment of oncological diseases such as relapsed refractory CD30-positive lymphoma including Hodgkin's disease. This drug was developed by Medarex, which was later acquired by Bristol-Myers Squibb.